Concepedia

Author

Shiguang Ye

Tongji Hospital

Also Known As

SHI-GUANG YE, SHIGUANG YE, Shi-Guang Ye, Shiguang Ye

38

Publications

213

Citations

8

H-Index

24

Concepts

All Affiliations

Tongji HospitalTongji UniversityShanghai Jiao Tong UniversityShanghai Institute of HematologyUniversity of Maryland, Baltimore
SY

About

Shiguang Ye is an author at Tongji Hospital specializing in medicine, radiation oncology, and immunology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

61

2

Immunology

2

2

61

3

Cell Biology

1

1

40

4

Cellular Therapies

1

1

21

5

Clinical Immunology

1

1

21

Shiguang Ye

×

7

Publications

167

Citations

7

H-Index

YearCitations

SIRT1 downregulation enhances chemosensitivity and survival of adult T-cell leukemia-lymphoma cells by reducing DNA double-strand repair

Liang Li, Shiguang Ye, Meng Yang,

Oncology Reports

2015

42

SIRT1 inhibition impairs non-homologous end joining DNA damage repair by increasing Ku70 acetylation in chronic myeloid leukemia cells

Wenjun Zhang, Haixia Wu, Meng Yang,

Oncotarget

2015

40

Risk of HBV Reactivation in Patients With Resolved HBV Infection Receiving Anti-CD19 Chimeric Antigen Receptor T Cell Therapy Without Antiviral Prophylaxis

Ping Li, Lili Zhou, Shiguang Ye,

Frontiers in Immunology

2021

24

Safety and efficacy of a novel anti-CD20 chimeric antigen receptor (CAR)-T cell therapy in relapsed/refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL) patients after failing CD19 CAR-T therapy.

Aibin Liang, Shiguang Ye, Ping Li,

Journal of Clinical Oncology

2021

21

C-CAR039, a Novel Anti-CD20/CD19 Bi-Specific CAR T-Cell Therapy Shows Deep and Durable Clinical Benefits in Patients with Relapsed or Refractory (r/r) B-Cell Non-Hodgkin Lymphoma (B-NHL) in Long Term Follow up

Ping Li, Wenjuan Yu, Lili Zhou,

Blood

2023

16

A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma

Wenjuan Yu, Ping Li, Lili Zhou,

Blood

2025

14

Different sites of extranodal involvement may affect the survival of patients with relapsed or refractory non-Hodgkin lymphoma after chimeric antigen receptor T cell therapy

Lili Zhou, Ping Li, Shiguang Ye,

Frontiers of Medicine

2020

10

Page 1